<SEC-DOCUMENT>0000939767-25-000111.txt : 20250728
<SEC-HEADER>0000939767-25-000111.hdr.sgml : 20250728
<ACCEPTANCE-DATETIME>20250728160907
ACCESSION NUMBER:		0000939767-25-000111
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250728
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250728
DATE AS OF CHANGE:		20250728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0102

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		251155651

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel-20250728.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:03a946d1-9e23-4c56-8ba3-d276d68c8984,g:ddc33eae-bdc9-4770-a755-01724e1b0c19,d:92904b6704ff40f5a10b1aa874377b70-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20250728</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20250728.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-28</xbrli:startDate><xbrli:endDate>2025-07-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i92904b6704ff40f5a10b1aa874377b70_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:108.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">July 28, 2025</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"/><td style="width:198.25pt"/><td style="width:1.0pt"/></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="exel-20250728_g1.jpg" alt="Exelixis_Logo_RGB_2023.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:177px" id="i-1"/></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">EXELIXIS, INC.</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"/><td style="width:38.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.145%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30235</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">04-3257395</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1851 Harbor Bay Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Alameda</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">837-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:39.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.363%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock $0.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i92904b6704ff40f5a10b1aa874377b70_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;28, 2025, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter ended July&#160;4, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) &#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.967%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20250630exhibit991.htm">Press Release issued July 28, 2025</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i92904b6704ff40f5a10b1aa874377b70_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"/><td style="width:26.608%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.526%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 28, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey J. Hessekiel</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jeffrey J. Hessekiel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and General Counsel <br/></span></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exel20250630exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ida61e210a9d54afebeeef614ef0afa40_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-top:9pt"><img alt="imagea.jpg" src="imagea.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:175px"></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Contacts&#58;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chris Senner</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-7240</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">csenner&#64;exelixis.com</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Susan Hubbard</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">EVP, Public Affairs &#38; Investor Relations</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-8194</font></div><div style="text-align:right"><font style="color:#006ba6;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">shubbard&#64;exelixis.com</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Announces Second</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Quarter 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Results and Provides Corporate Update</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Total Revenues of $568.3 million, Cabozantinib Franchise U.S. Net Product Revenues of $520.0 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">-</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- GAAP Diluted EPS of $0.65, Non-GAAP Diluted EPS of $0.75</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">-</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">- Conference Call and Webcast Today at 5&#58;00 PM Eastern Time -</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ALAMEDA, Calif.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">July&#160;28, 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> - Exelixis, Inc. (Nasdaq&#58; EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Exelixis continued to execute on our corporate objectives in the second quarter of 2025, delivering on key commercial, development and pipeline milestones,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. &#8220;While early in the launch, we&#8217;re very pleased with the reception that CABOMETYX&#174; has received in advanced neuroendocrine tumors (NET). Our commercial team rapidly mobilized on the U.S. NET launch following approval in March, capturing a leading share of new patient starts among oral therapies in second-line and later settings with NET representing approximately four percent of our overall CABOMETYX business in the second quarter. We will continue to track the launch trajectory and provide updates to our 2025 full year financial guidance, as appropriate.&#8221; </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Morrissey continued&#58; &#8220;Turning to the zanzalintinib development program, in June, we announced positive topline results from the STELLAR-303 pivotal study in colorectal cancer. We plan to discuss these results with regulators with the intention of filing for approval in this indication as quickly as possible. In May, we completed enrollment into the STELLAR-304 pivotal study in non-clear cell renal cell carcinoma with top-line results expected in the first half of 2026, depending on study event rates. Based on our evaluation of emerging data from the phase 2 portion of the STELLAR-305 study in advanced squamous cell carcinoma of the head and neck, emerging competition in this indication and assessment of other potentially larger commercial opportunities, we have made the decision not to proceed to the phase 3 portion of the trial. We also initiated the STELLAR-311 pivotal study in advanced NET during the quarter and plan to announce an additional wave of zanzalintinib pivotal trials in the coming months. Finally, our early-stage pipeline is advancing quickly with phase 1 clinical studies ongoing for our XL309, XB010 and XB628 programs, and XB371 moving into clinical investigation. As we look ahead to the second half of the year, I&#8217;d like to thank the entire Exelixis team for their continued execution across our business, and for their dedication to our mission to help cancer patients recover stronger and live longer.&#8221; </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 2 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">July&#160;28, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Second Quarter 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Results</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total revenues </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended June&#160;30, 2025 were $568.3&#160;million, as compared to $637.2&#160;million for the comparable period in 2024. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues for the quarter ended June&#160;30, 2025 included net product revenues of $520.0 million, as compared to $437.6&#160;million for the comparable period in 2024. The increase in net product revenues was primarily due to an increase in sales volume.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Collaboration revenues, composed of license revenues and collaboration services revenues, were $48.2&#160;million for the quarter ended June&#160;30, 2025, as compared to $199.6&#160;million for the comparable period in 2024. The decrease in collaboration revenues was primarily related to a $150.0 million commercial milestone recognized during the second quarter of 2024 in connection with Ipsen achieving $600 million in cumulative net sales of cabozantinib in its related license territory over four consecutive quarters.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2025 were $200.4&#160;million, as compared to $211.1&#160;million for the comparable period in 2024. The decrease in research and development expenses was primarily related to decreases in manufacturing costs to support our development candidates and clinical trial costs, partially offset by increases in stock-based compensation, consulting and outside services, and personnel expenses.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2025 were $134.9 million, as compared to $132.0 million for the comparable period in 2024. The increase in selling, general and administrative expenses was primarily related to increases in marketing expenses, stock-based compensation, and personnel expenses, partially offset by a decrease in corporate giving.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Provision for income taxes </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended June&#160;30, 2025 was $45.6 million, as compared to $66.7&#160;million for the comparable period in 2024.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP net income</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for the quarter ended June&#160;30, 2025 was $184.8&#160;million, or $0.68 per share, basic and $0.65 per share, diluted, as compared to GAAP net income of $226.1&#160;million, or $0.78 per share, basic and $0.77 per share diluted, for the comparable period in 2024. GAAP net income per share for the quarter ended June&#160;30, 2025 was favorably impacted by lower weighted-average common shares outstanding for the quarter ended June&#160;30, 2025, as compared to the comparable period in 2024, as a result of the stock repurchase programs.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP net income </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">for the quarter ended June&#160;30, 2025 was $212.6&#160;million, or $0.78 per share, basic and $0.75 per share, diluted, as compared to non-GAAP net income of $245.6&#160;million, or $0.85&#160;per share, basic and $0.84 per share diluted, for the comparable period in 2024. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP Financial Measures</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To supplement Exelixis&#8217; financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net income (and the related per share measures), which excludes from GAAP net income (and the related per share measures) stock-based compensation, adjusted for the related income tax effect for all periods presented.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare Exelixis&#8217; results from period to period, and to identify operating trends in Exelixis&#8217; business. Exelixis has excluded stock-based compensation, adjusted for the related income tax effect, because it is a non-cash item that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 3 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">July&#160;28, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis&#8217; business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">2025 Financial Guidance </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is maintaining the previously provided financial guidance for fiscal year 2025. </font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.597%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline"> </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.25 billion - $2.35 billion</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$2.05 billion - $2.15 billion</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4% - 5% of net product revenues</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development expenses </font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$925 million - $975 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$475 million - $525 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective tax rate</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21% - 23%</font></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exelixis&#8217; 2025 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.8% for CABOMETYX effective Jan. 1, 2025.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $50.0 million of non-cash stock-based compensation.</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $80.0 million of non-cash stock-based compensation.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Second Quarter 2025 Highlights </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cabozantinib Franchise Net Product Revenues and Royalties.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Net product revenues generated by the cabozantinib franchise in the U.S. were $520.0 million during the second quarter of 2025, with net product revenues of $517.9 million from CABOMETYX (cabozantinib) and $2.1 million from COMETRIQ&#174; (cabozantinib). Based upon cabozantinib-related net product revenues generated by Exelixis&#8217; collaboration partners during the quarter ended June 30, 2025, Exelixis earned $43.4 million in royalty revenues. </font></div><div style="margin-top:9pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Partner Ipsen Received Approval from the European Commission (EC) for CABOMETYX for Patients with Previously Treated Advanced NET. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July, Exelixis announced that its partner Ipsen received approval from the EC for CABOMETYX for adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This approval follows the positive opinion received from the European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use in June 2025 and allows for the marketing of CABOMETYX in this indication in all 27 member states of the European Union (EU), Norway, Liechtenstein and Iceland. In March, Exelixis received approval from the U.S. Food and Drug Administration (FDA) for CABOMETYX in this setting. These approvals were based on the positive results of the phase 3 CABINET pivotal trial, which evaluated CABOMETYX compared with placebo in two cohorts of patients with previously treated NET&#58; advanced pNET and advanced epNET. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 4 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">July&#160;28, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Announcement of Positive Top-line Results from the Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer (CRC). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In June, Exelixis announced positive top-line results from the phase 3 STELLAR-303 pivotal trial in which the combination of zanzalintinib with atezolizumab (Tecentriq&#174;) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population. The STELLAR-303 study is evaluating zanzalintinib in combination with atezolizumab versus regorafenib in patients with metastatic, refractory non-microsatellite instability-high or non-mismatch repair-deficient (non-MSI-H&#47;dMMR) CRC. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The top-line findings were from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases or NLM). The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. Exelixis plans to discuss these results with regulators with the intention of filing for approval in this indication as soon as possible. Detailed results will be presented at a future medical meeting. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Presentation of Encouraging Results from Phase 1b&#47;2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In June, Exelixis presented results from multiple dose-escalation cohorts of patients with advanced solid tumors, and an expansion cohort of patients with previously untreated advanced clear cell renal cell carcinoma (ccRCC) from the phase 1b&#47;2 STELLAR-002 trial evaluating zanzalintinib in combination with either nivolumab (Opdivo&#174;) or a fixed-dose combination of nivolumab and relatlimab (Opdualag&#8482;) at ASCO 2025. The results from the ccRCC expansion cohort demonstrated encouraging activity across all efficacy parameters, including objective response rate (ORR), progression-free survival (PFS) and disease control rates. The findings from the dose-escalation cohorts showed that the toxicity profile of these combinations was manageable and consistent with each agent administered as monotherapy. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zanzalintinib Pivotal Development Program Updates. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Today, Exelixis announced several updates to the zanzalintinib development program, including&#58; </font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-12.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.13pt">STELLAR-304 study enrollment completed in May 2025. STELLAR-304 is a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in previously untreated patients with advanced non-clear cell renal cell carcinoma (nccRCC). The primary endpoints in the trial are PFS and ORR. Top-line results are expected in the first half of 2026, depending on study event rates.</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-12.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.13pt">Based on the company&#8217;s evaluation of emerging data from the phase 2 portion of the STELLAR-305 trial in advanced squamous cell carcinoma of the head and neck (SCCHN), emerging competition in this indication, and assessment of other, potentially larger, commercial opportunities, Exelixis has decided not to proceed to phase 3. </font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-12.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.13pt">Initiation of the STELLAR-311 phase 3 pivotal trial in advanced NET. STELLAR-311 is evaluating zanzalintinib versus everolimus as a first oral therapy in patients with advanced NET, regardless of site of origin. The primary endpoint of the trial is PFS per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review.</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-12.6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:7.13pt">Plans to announce the next wave of zanzalintinib pivotal trials in the coming months. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Preclinical Data Presentations from Four Pipeline Programs in Advanced Cancers at the American Association for Cancer Research Annual Meeting (AACR 2025). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In April, Exelixis presented preclinical data from four pipeline molecules at AACR 2025. Presentations included data for XL309 and XL495, small molecules that have demonstrated synthetic lethality in the context of certain genetic anomalies found in varying frequencies across a broad array of tumor types. The XL309 findings demonstrated activity of XL309 as monotherapy or in combination with PARP or topoisomerase inhibitors. Data analysis from the XL495 program demonstrated the potential for anti-tumor activity both as monotherapy and in combination with DNA-damaging agents. However, </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 5 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">July&#160;28, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">based on early clinical data generated for XL495, Exelixis has discontinued further development of this program. Preclinical data were also presented for the PD-L1 + NKG2A-targeting bispecific antibody XB628 and for the tissue factor (TF)-targeting antibody-drug conjugate (ADC) XB371. Data analysis from the XB628 program demonstrated the molecule&#8217;s tumor cell killing activity both </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vitro</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, supporting advancement of this molecule into clinical development. Findings from XB371 non-clinical experiments demonstrated potent</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">anti-tumor activity </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> across a range of human tumor xenograft models including colorectal, lung, and pancreatic cancers, supporting the molecule&#8217;s advancement into phase 1 clinical development. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Advancement of XB628 and XB371 Pipeline Programs into Clinical Development.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Today, Exelixis provided an update on the recent progress of its early-stage pipeline programs, including XB628 (PD-L1 + NKG2A-targeting bispecific antibody) and XB371 (TF-targeting ADC). In April, Exelixis initiated the phase 1 study of XB628, following the U.S. FDA clearance of its Investigational New Drug (IND) application in March. Exelixis now has three ongoing phase 1 trials for its pipeline programs XL309, XB010 and XB628. Additionally, in July, the U.S. FDA cleared Exelixis&#8217; IND application for XB371 and the company plans to initiate the phase 1 study in the coming months. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Federal Income Tax Impact from the One Big Beautiful Bill Act.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> On July 4, 2025, the One Big Beautiful Bill Act was signed into law which, among other provisions, permanently repeals the requirement to capitalize domestic research and experimental (R&#38;E) expenditures for federal income tax purposes for taxable years beginning after December 31, 2024, and allows for the accelerated deduction of any remaining unamortized domestic R&#38;E expenditures. Foreign R&#38;E expenditures are still required to be capitalized and amortized ratably over 15 years. Exelixis estimates its federal cash tax benefit for previously unamortized domestic R&#38;E expenditures is $147 million with no corresponding impact to the federal income tax provision.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Positive Developments Across Cabozantinib Patent Estate.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Today, Exelixis announced recent positive developments with regards to the company&#8217;s defense of its cabozantinib patent estate. First, in June and July 2025, the United States Patent and Trademark Office (USPTO) declined to institute Azurity Pharmaceuticals&#8217; petitions for </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">inter partes </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">review (IPRs) of U.S. Patent Nos. 11,298,349 and 12,128,039, respectively. Second, in July 2025, Exelixis entered into a settlement agreement with Biocon Pharma Limited, which resolved the patent litigation Exelixis brought in response to Biocon&#8217;s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of CABOMETYX prior to the expiration of the applicable patents. Pursuant to the terms of the agreement, Exelixis will grant Biocon a license to market its generic version of CABOMETYX in the U.S. beginning on January 1, 2031, if approved by the FDA and subject to conditions and exceptions common to agreements of this type. </font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Repurchase Program. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In August 2024, Exelixis&#8217; Board of Directors authorized a stock repurchase program to acquire up to $500 million of the company&#8217;s common stock before December 31, 2025. In February 2025, the Board of Directors authorized the repurchase of up to an additional $500 million of the company&#8217;s common stock before December 31, 2025. Under these programs, as of June 30, 2025, Exelixis has repurchased $796.3 million of the company&#8217;s common stock, at an average price of $36.69 per share. Since the approval of the first stock repurchase program in March 2023, the weighted-average diluted common shares outstanding has decreased from 326.3 million shares to 284.4 million shares as of June 30, 2025. Stock repurchases under these programs may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The timing and amount of any stock repurchases under the stock repurchase programs will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of our common stock and general market conditions. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 6 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">July&#160;28, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Basis of Presentation</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis has adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December&#160;31. For convenience, references in this press release as of and for the fiscal periods ended July&#160;4, 2025 and June&#160;28, 2024, are indicated as being as of and for the periods ended</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June&#160;30, 2025 and June&#160;30, 2024.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conference Call and Webcast</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis management will discuss the company&#8217;s financial results for the second quarter 2025 and provide a general business update during a conference call beginning at 5&#58;00&#160;p.m. ET &#47; 2&#58;00&#160;p.m. PT today, Monday, July&#160;28, 2025.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To access the conference call, please register using this </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">link</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and proceed to the Event Calendar page under the Investors &#38; News heading. A webcast replay of the conference call will also be archived on </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for one year.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Exelixis</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX&#174; (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, follow </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#64;ExelixisInc</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on X (Twitter), like </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis, Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on Facebook and follow Exelixis on LinkedIn.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, including, without limitation, statements related to&#58; Exelixis&#8217; plans to discuss the results of STELLAR-303 with regulators and intention of filing for approval in this indication as soon as possible&#59; anticipated timing for zanzalintinib pivotal data milestones with respect to the STELLAR-304 and STELLAR-311 trials and plans to announce additional zanzalintinib pivotal trials&#59; Exelixis&#8217; assessment of other potential commercial growth opportunities&#59; Exelixis&#8217; plans to present data from STELLAR-303 at a future medical meeting&#59; Exelixis&#8217; plans to initiate the phase 1 study for XB371 in the coming months&#59; the terms of Exelixis&#8217; settlement agreement with Biocon Pharma Limited which is subject to FDA approval and subject to conditions and exceptions common to agreements of this type&#59; and Exelixis&#8217; scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation&#58; the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis&#8217; and its partners&#8217; ability to obtain or maintain coverage and reimbursement for these products&#59; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products&#59; the level of costs associated with Exelixis&#8217; commercialization, research and development, in-licensing or acquisition of product candidates, and other activities&#59; Exelixis&#8217; ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so&#59; the availability of data at the referenced times&#59; the potential failure of cabozantinib, zanzalintinib and </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 7 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">July&#160;28, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and&#47;or efficacy in clinical testing&#59; uncertainties inherent in the drug discovery and product development process&#59; Exelixis&#8217; dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved&#59; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere&#59; Exelixis&#8217; continuing compliance with applicable legal and regulatory requirements&#59; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib, zanzalintinib and other Exelixis product candidates&#59; Exelixis&#8217; dependence on third-party vendors for the development, manufacture and supply of its products and product candidates&#59; Exelixis&#8217; ability to protect its intellectual property rights&#59; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis&#8217; marketed products&#59; changes in economic and business conditions, including as a result of changing trade policies and tariffs and the related uncertainty thereof&#59; and other factors detailed from time to time under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis&#8217; other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered trademarks of Exelixis, Inc.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Opdivo&#174; is a registered trademark of Bristol Myers Squibb.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Opdualag&#8482; is a trademark of Bristol Myers Squibb.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">TECENTRIQ (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-see attached financial tables-</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="ida61e210a9d54afebeeef614ef0afa40_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 8 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">July&#160;28, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:36.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net product revenues</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">520,014&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">437,581&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,033,297&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">816,104&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Collaboration revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">48,247&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">199,597&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">90,411&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">246,300&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">568,261&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">637,178&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,123,708&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1,062,404&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19,470&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,667&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38,642&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38,923&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200,356&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">211,147&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">412,589&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">438,836&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">134,859&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">132,015&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">272,042&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">245,999&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Restructuring</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">475&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33,310&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">354,685&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">361,304&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">723,273&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">757,068&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">213,576&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275,874&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">400,435&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">305,336&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,789&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17,258&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35,865&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37,152&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Other income (expenses), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(287)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(195)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(376)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">230,415&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">292,845&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">436,105&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">342,112&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45,567&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">66,729&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">91,641&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">78,679&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">184,848&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">226,116&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">344,464&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">263,433&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.68&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.78&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.89&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.65&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.77&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.88&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">272,583&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">289,216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275,693&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">294,986&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">284,393&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">293,974&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">286,285&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">299,752&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;- more - </font></td></tr></table></div></div></div><div id="ida61e210a9d54afebeeef614ef0afa40_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:57.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exelixis Second Quarter 2025 Financial Results</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Page 9 of 9</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">July&#160;28, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:36.306%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">184,848&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">226,116&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">344,464&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">263,433&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - research and development</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14,143&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9,178&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23,665&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13,070&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stock-based compensation - selling, general and administrative</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21,928&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16,176&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38,336&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31,397&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(8,355)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(5,841)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(14,348)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(10,289)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">212,564&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">245,629&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">392,117&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">297,611&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.68&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.78&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.89&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted&#160;</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.65&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.77&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.88&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.78&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.85&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.42&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted </font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.75&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.84&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.37&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">0.99&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">272,583&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">289,216&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">275,693&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">294,986&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">284,393&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">293,974&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">286,285&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">299,752&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:7.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash stock-based compensation used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>exel-20250728.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:03a946d1-9e23-4c56-8ba3-d276d68c8984,g:ddc33eae-bdc9-4770-a755-01724e1b0c19-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20250728" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20250728">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20250728_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20250728_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>exel-20250728_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:03a946d1-9e23-4c56-8ba3-d276d68c8984,g:ddc33eae-bdc9-4770-a755-01724e1b0c19-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_bed7de8c-43dd-4cd3-802c-5215fd909809_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_73b5704b-3e21-4678-8ba0-94c30445d52e_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_84241dc2-7e04-44f8-98e0-db26bd234b2d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_57e08296-5aaa-432e-a332-d6850c17b356_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d37abe30-7b61-4e0f-a9f2-53bd981a5b7e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_c837857a-11ae-4780-a5a2-260d8ea732c3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8203b3b3-6b96-4d49-9ea3-39dba4733143_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a1805685-3e70-47a9-b2ea-cec8d9c97118_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_fbf2e830-9aac-47e1-830a-c25bca1e7f33_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_47b45904-8097-4106-bb0d-495c4759335f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_00c2c986-cba5-4369-a23b-72126b472bb1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_46330c5d-c411-4705-bbac-6e6317c622ed_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_285b4ae0-5953-4dd1-8a8f-f079d1e3842c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a292aaae-8d35-49ab-b780-edde78974f9c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_355827e1-401b-42d3-93bd-740481cab0a2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_271a61d0-47ae-4b68-92fb-b29764b5fe42_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_18c5c6ef-04d7-457a-8330-38d497823c9f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_48364621-ff45-4db9-9425-be6ba0c4a891_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0f4a52b0-d11b-43c8-9b00-7eb8dab0d533_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a92bd27b-fc31-43cf-81ae-8bb8d6b8baef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b3823e84-d971-4ee1-b462-c18b07a8ff59_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_845d907c-938b-41fa-8d91-a1d922809c09_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_cf77beef-4074-45e9-b7fa-953f635889bc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>exel-20250728_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:03a946d1-9e23-4c56-8ba3-d276d68c8984,g:ddc33eae-bdc9-4770-a755-01724e1b0c19-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20250728.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0b0a57eb-e50c-4894-b828-db8a824bb0f2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_AmendmentFlag_0b0a57eb-e50c-4894-b828-db8a824bb0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_55fe0da3-1654-443c-beb9-f6914b882e6d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_DocumentPeriodEndDate_55fe0da3-1654-443c-beb9-f6914b882e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_815fc85d-9c54-4759-95c4-ab97c83324f1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_EntityRegistrantName_815fc85d-9c54-4759-95c4-ab97c83324f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_98229847-1ee0-40fa-a1e5-fe0679aacb66" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_EntityCentralIndexKey_98229847-1ee0-40fa-a1e5-fe0679aacb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e6f10c74-1f54-48de-a1fd-506028bac7fa" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_EntityEmergingGrowthCompany_e6f10c74-1f54-48de-a1fd-506028bac7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_714f51c8-1937-4ded-9910-341618df390e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_Security12bTitle_714f51c8-1937-4ded-9910-341618df390e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_68652b24-2f62-43ce-a850-27bfcc42b70b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_TradingSymbol_68652b24-2f62-43ce-a850-27bfcc42b70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_f052c615-dae3-4ca7-b5b3-464e34a288cc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_SecurityExchangeName_f052c615-dae3-4ca7-b5b3-464e34a288cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f13f7076-1f24-4be5-9822-f413504cdb85" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_EntityFileNumber_f13f7076-1f24-4be5-9822-f413504cdb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_53aa3f48-76f0-4632-bbbd-3c01a7e4c14b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_53aa3f48-76f0-4632-bbbd-3c01a7e4c14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6a937ac9-c420-431a-809c-df552f235302" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_EntityTaxIdentificationNumber_6a937ac9-c420-431a-809c-df552f235302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e8e20f84-d060-48d6-b15f-8aec957b19a8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_EntityAddressAddressLine1_e8e20f84-d060-48d6-b15f-8aec957b19a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c7dfc737-adca-4de6-a2e4-da13ed0af4a6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_EntityAddressCityOrTown_c7dfc737-adca-4de6-a2e4-da13ed0af4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9c8c17d6-c18f-48d0-9294-75db955de7b0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_EntityAddressStateOrProvince_9c8c17d6-c18f-48d0-9294-75db955de7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1028df9d-7775-4426-99db-72c2b96a580e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_EntityAddressPostalZipCode_1028df9d-7775-4426-99db-72c2b96a580e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4cac304b-6075-47ef-a1cc-959e309024b3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_CityAreaCode_4cac304b-6075-47ef-a1cc-959e309024b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e1271a85-ff1c-4e60-a9fb-f551630da77c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_LocalPhoneNumber_e1271a85-ff1c-4e60-a9fb-f551630da77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_933fff27-a31a-403f-ac0f-23651aae2b59" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_WrittenCommunications_933fff27-a31a-403f-ac0f-23651aae2b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_2b63a228-6a97-4300-a887-8823e1c8f5ca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_SolicitingMaterial_2b63a228-6a97-4300-a887-8823e1c8f5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c634a8fd-fc6e-4329-bb28-423ba585104c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_PreCommencementTenderOffer_c634a8fd-fc6e-4329-bb28-423ba585104c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f6208328-5193-4714-aa2d-41864b401d79" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f6208328-5193-4714-aa2d-41864b401d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8bc34e74-47be-4f86-983c-6a9fc0a31966" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_96afbb27-e297-4ca3-b76e-720e2d772cfb" xlink:to="loc_dei_DocumentType_8bc34e74-47be-4f86-983c-6a9fc0a31966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exel-20250728_g1.jpg
<TEXT>
begin 644 exel-20250728_g1.jpg
M_]C_X0TO17AI9@  34T *@    @ # $   ,    !#.0   $!  ,    !"?8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D
M,C R,CHP-SHR-2 Q.#HQ,#HR-@      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   $L* #  0    !   !1P         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
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MDI__V?_M%2I0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"!0 617AE;&EX:7-?3&]G;U]21T)?,C R,CA"24T$)0      $.Z*
M+VTF;HFD<OR1I?7(F<@X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  :0!8 #8 .  P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              %'   $
ML    !8 10!X &4 ; !I '@ :0!S %\ 3 !O &< ;P!? %( 1P!" %\ ,@ P
M #( ,@    $                          0             $L    4<
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<
M    4F=H=&QO;F<   2P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "\$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &1
M 0, $ ," P8               #_VP"$  (" @(" @(" @(# @(" P0# @(#
M! 4$! 0$! 4&!04%!04%!@8'!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P!
M P,#!00%"08&"0T*"0H-#PX.#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_" !$( 4<$L ,!$0 "$0$#$0'_Q $/  $
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M P$! A$#$0   +_
M
M
M                                         #%O'^1Z4Y4Y!QL
M
M#X8^^+]SBOS_ *<F?>X_N],@   !T#X_VZT.BO0-K_H?S3O]L0
M                                                      !COXOW
M:W^D.^\4\>Y)JF.?_9^*?_<72<FN=]>@  #A_P WZJI///I2:7:/4TH>?==
M
M    #C\=ZB_.'I[I?R_J@#7,6F^@/.6:.4<3  &B)K-Z)]!]2^=].U_T/YIU
MS
M       C-P3L&N'I'OGX  28YUP"R#N_H0  0:ZG[BA7U=VS:5W]YSS?ROB
M
M     $,^L.UX)]2]Q@ #,_)^*VH^@O-X $:N#<_K=Z/[\D)S/@]F?>WGP
M
M   1[X9SBLOHGT&0 !*OL+KBPWN?HP 8LX_R.JOS[Z1VF6EM_HWS)D/[7P@
M
M    !^5;53>>O2>)>.\E '([XVQ>A_-&1?M_" ZW^']]3WG?TOTSYGU)<=C=
M96 =Q])        #B#A)C?1/8C4   #X=6.SFL     Z:5*:98)F-     !M
MB_W+;L1$NU:F[YZ@<HF85;6<4ON    =6*.=<NL( ^ESF>N>8D<*5-:9QNFO
MX@     NYSUR[$@"O&](&6IQ1D--Z>6H    &R*L;YQ.M7:DD(M<-GH.G_,^
MK6]TAWWH@/TM&8N3<5FWVIU%R>_YQU[\7[H"=/\ =<;^#\]V.6V8.2\6GWW!
MTKE_DO%@-O2]7'0/HS"W%^5\S^G\UOGI+R[V/]WX ,=3%3M\\)3&DL>I>?%;
M@  11M6ORU(I6C&J/S/LNPPSG$ROK:>=;YUB0!C:8K0O3M4.()YUOG*)
M%'&F4);5      VAZ@L=^U I0TR@;:H L4K>XW/0  #045:Y0VFH M I>V&F
M@%0&F=;MJ      #T69;9UB0(CVK0IIEJ!E5/I,QV     J?OG5_>GP$MHM?
M7EJ!7]TYW=$GKGLSX 2'YIP>S'O7SZ /QK?\*7WNN( %?737=\3.N^R_I.GM
MKIV9W9_4X \]VN,;Y@"VBFEG-+@ =3*5=<H9374   #X3-K:X&FF5(D59WIW
MX_8Z@<2BTVF@    \UFV.,4      =@/3OCON@<.>>W7'!$P!I+K<])[5N
M*NKTJBOG] )91:^G+7]@#SZ:XQIF      /U/33COW, JWOG5->@&54^DS'8
M    "@77*+$U EM%KZ\M0.'_ #?JJ(\W^H.K?/\ H ?$V6=Y] 2-YMP,   "
M)O779E?'3?=_U'=?J?*MW](>7]YKD!M#RT;8?0"VBFEG-+@#B#S[ZXQ]F
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M"VBFEG-+@8<F/-]KCK +#ZWN0STU             \TVV.-T 6KTO:530
M    #IB/._KEC&8 _0_, &?HGT&Y;<L   >?+7&-<P!8M6]Q>>@      JUO
MG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !MJ:5+^=/3../B?= )GQV_P!+
M3 [*ZM$+>KNV8,]3]Q$#<WI;CZ.\Q]^^Q\0  ; \M6V&L MHII9S2X'#'E[V
MP_, ^&?XF>M;R[K;.$3K           /--MCC= $Q*VEY%@  !VR)GK6P
M$=)CS]:X\<  #M9Z'LMLL1(   \^6N,:Y@"3\6G#6P   W4+%ZW  JUOG51>
M@&54^DS'8    "@/7*+4U EM%KZ\M0  ,+<6Y;5CY_\ 1WQ '*_H_/;KZ/\
M,.*N/\DK-Z)]!:( 2][)ZPGWW!TH  !L#RU;8:P"VBFEG-+@"B33*'-J@ #0
M=R)/UM+F+37K;(<2         /--MCC=      S/$^CK+8    5Z7I3/?/4
M#47NYZS"K8   #SY:XQKF     !S!ZB<=P *M;YU47H!E5/I,QV     H#UR
MBU-0);1:^O+4   5X=+]Z16Z^[& &;N5<1Q3Q[DO#_F_2!S7ZORV_P#I/RYS
M_P"S\0  &P/+5MAK +:*:6<TN ,,3'GKUQZR    :R:-;6P4TS;$@
M#S3;8XW0     ,\Q/HHRV    'YGF^UQQ', "4T6O[RU    'GRUQC7,
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M2J:        8IF//!KCU, Y(V1^0!E)/H?RU[A$@  >?+7&-<P!8M6]Q>>@
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M->0?L_# P=Q/F%7'07HL@#G/U_DMV]'^8.S?O^> !L#RU;8:P"VBFEG-+@
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M*GO/'I;9Y: ;O3.VOT7YER%]KX8V!Y:ML-8-9Z$<MI&Q( ZV53Z9UUVIQP
M !^Y976]L^>FX        *6=,^F3     'TR?$VB4OD6)$/[5KFO0 97B;?\
M]-8   /Q*YKTBG-=C(:2U//21$2*CM,\+S      [Y"SRFF88D 07M2!UZ@
M  #L$+%:WE)6P%36F>"YC<0E)%K**7_4 K^Z<[MB1USV;N;UM'[^\YYHY1Q,
M     8FX[R:(?6W:'7_Q_M S5RGB4R^SNJ1M"B_7+4<O"?5;S(K8  #I$Q!>
MU8BS6/MHQZC9&HY\S=$RVK:P2M\PQ(
M                    Q[\;[E2'G+TYMZ7L)[EZ/EAV)UH
M    !MSB#]CF#Z
M      5H=%^@8[\*YS++L7K2P7N3I
M                                          86XORVJ_S]Z.S5RCB=
MH_?WG/<7H
M                    !IB:I?/7I/JWS_I6P>B/-/9?W?/
M                                                           $
M9^"=@UW]+]Z6I^@O-V5>0\;
M                                   &USTJ(\W^H9U=M=-27YUU^
M
M         !#?K+M7KWXOW3I[:Z<
M                                        &!.(<TSSR[AFJ8
M
M
M                                                       __]H
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MC3+QB;C/,:P5*@C&,8<90ED55\!0*%0D++*BX*3& ("&F?3 PMW8#!G,'Z>
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M5U0ZG%827+'Q%YH3\@^].,B"L'2HMR^(^)H'R%#/LW4&ZAG,._@0XUAQ -V
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M<(JG4>['Z"5F^@E9OH)6:4T%628K'L#=@;L#";?0 =F [ 8&WR]@83L(B/\
MN=?5RI<&=X=X81V:2)7&#)_HV_\ NR>%OW^,:1Y8]Z/[$IN6_A<$ ;-*TN&6
M'[MV5V7V(B.S32M"J1J.DOE2)34YRGP_L2GM;]RA(:&>1#R6T!VCPWL2>O2N
MB+:J=4C),ECX<Z]B=1%K_&ZD66.X^Q0),@WD6   ?\:__]H " $#  $% /\
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M/WPXCO@N*Q$J"?OSOWF@3,8=]4!V8H[X?_1^!W "A^AN=(>=4I=LHANPAME
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M[F:WJ:?+\:$_?'3O7_)W&QC\F\T9"0T?"55IY%4SG+):S4[XJE87*5H-!E
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MR401)^UI-@%YHV\,(+8HZJ"P:[SF3H+N\@19CQ 7DX "LT7=Y-U;->[7L?P
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M0?=IE7*%1ZK#FMQ7Y$T>1-$'0D$9C[5>0VHB2E;M^"+VF]0KUJDL!54  "P
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M7L@Y9H\O4"*.ODA3&HJ7&V2IJ&QDF<\[.Q/XN0]NS?E>U9GHI%*&FN=)#5*
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M%;*2NJ9*(PPO*&(>0),S8#=YACV*2T%HK=G*Q=969(S Z_P]45P:"8C68)P
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M@RL#@58'80=1'(M69[))U=SL\XF@4DA94V20OAZB5"5/IX\VEHS19I-^BNT
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M0\C)GU5?/$SR:^[W.H6DM]LIY*JMJ7. 2*)2S,?Q#2\9LKPT?\QDW;=2-_\
MQZ./N8(O3"ZVZ6)]%<WYCI=[)]FGPH:20=S<JN(XX$'488B.ZYF;N=@;3 #
M#8.P)GNRTIDOF5XB+K%$I+U-MUL^H;6@.+CV.\.C0%3B",01SCD6[,U-ORT(
M_=;_ $*G^(H9".L&'.T9&^G;&'/I1W.W5*5E!<(4J**JC.*212*&1E/00<>1
M<OBLWN#H?;O[H\CB_P#7]N\1'(CX(T-/5V?+&7(Z:ZW]YXWA-XJIEWZ<Q[P'
M64U/TC4TN/\ ICE*TD:NR:T8@$J>D'FT$>5^)>:+%$-D%-=*DQ#M=5([I_\
M;H$BXN72I"@C>JZ:AG;7TEZ?0QS<7+K3*1@6HZ>AIV_ZDIP=!)G3.=\S81LC
MNM?/4Q#THG<QC\2Z    #  ; !R'D<[J("SMT ;=(KK?:1J7.7$5XKU?:>0
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D%$%P$,8@B50ZQ* JAR1@-8.BHBA$0!411@ !J  &P#_RV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>imagea.jpg
<TEXT>
begin 644 imagea.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !+ 1,# 2(  A$! Q$!_\0
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M2W1^V&G2M<6%O*^-\D:NV.F2 3BK-5-)_P"059?]<4_]!%6Z19Y+^TO\;'^
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MM B>ZM-3FX"\<PMW*OP,>N"*_+M3E58C!Q^7>OI3]LC]I(_%KQ*_A?0+D_\
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M'PSX=T[0VN,"5K*V5&<#H"1R1[4M!ZG2W'_'K+_N'^5?B9=?\A*X_P"OEO\
MT8:_;.;_ (]9?]UOY5^)=V=NI3G_ *>F_P#1AIQ%+='[7Z3_ ,@JR_ZXI_Z"
M*MU3TD_\2NSX_P"6*?\ H(JWN]J@L^4_^"C/_)'M"_[#D7_HF6O"?^">?_)=
MKO\ [ D__HR*O=?^"C!_XL[H/_8<B_\ 1,M>%?\ !//_ )+M>?\ 8$G_ /1D
M57]DS^T?I"V,C(S7SY^U=X1L+C0K3Q%YL=O?V[BV*GK.C$_+[D=1[9KZ"9MO
M;-?&G[17Q"/C3QHVG6<A;3-+8PIM.1)-T=O?'W1]#7Q_$^(HT<OG&JKN6B7G
M_P  ^SX5P]>OF<)49<JAK)^7;YG(?#GQYJ?P]\2#4=,C-P[1M'+;<XE7!/./
M0\Y^M8>K:O=^)-8GU'4;DRWEU)OEGD/3/?Z =O05]3?L^_!>/PWI9UW6[=3J
M]Y%M2WD7/V:$_P .#_$1U_*O"_C7\-V^'/C*>")#_9-YF>S8C@+GYDSZJ2/P
M(K\SQF58["9;3JUI7A?X>U]FS]4P&;Y=C<VJT:,4JEK*7\UMU_EW/K[X:^&;
M#PGX-TS3=.99;=(5?SE_Y:LPR7SWSG-=1@5\\_LN?$[[98/X2U";=<VJ^98E
MF^]%W3/JN?R^E?0JMNQ7[#E.*HXS!4ZE!65K6[6/Q/-L)7P6-J4<0[RNW?O?
M6Y^-WQF_Y*WXY_[#=[_Z.:OU2_9]_P"2%^ _^P+:_P#HI:_*WXS?\E;\<_\
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MHR<[(4"#/K@5\SDN35<IJ3M5YH2Z6/J,\SZGG4*;E1Y:D=+WW78_'GXP?O\
MXP^-H8@TT[Z[>(D48W,S&9@% '))/%?J]\%M&O/#WPA\&Z9J$+6U]:Z3;0S0
MM]Y'$:@J?<&M]/"VDQ7GVN/2K%+O=O\ M"VR"3=G);=C.3SS6J.!7UY\>HV=
MS\NOVG/V=_B+X4\;:UXEUB&Y\6Z;?3M/_;EK"7VJ3D+)&.8MHP /N\9!KB_!
M?[2GQ*\!6B6FB^,KV.RC&%M+HI<(@]%$@.!["OUX9=WTKD]:^$?@GQ%(9-4\
M(Z)?R'GS)K"(L?QVYIW%R^9^5'Q ^.WCOXM+%9>)?$=SJUNKAH["-%CB+]CY
M: ;C]<U]-?L2?LRZWIOB6#XA>+-.ETN&UC8:38W*%9I'<$&9T(RJA6(4'DDY
MP,"OL/P_\,/"/A619-'\,:/I<JG(DM;&-''_  (#-=.HQ2N'+K<6BBBD6%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!_%*RUK7
M=(CT'10\3:HYANKX?=M;?'SM_O$?*![FN\J/UK&M3]K!P?70TIU'1FJBW6ID
M>$?"^G^$?#]GI.G0B"TMDVJHZD]V)[DGDFME5"]*%IU53A&G%0@K):"G.523
IG-W;U"DVBEHK0@3:*-HI:*5@"BBBF 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Jul. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 28,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.001 Par Value per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="exel-20250728.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="exel-20250728.htm">exel-20250728.htm</File>
    <File>exel-20250728.xsd</File>
    <File>exel-20250728_lab.xml</File>
    <File>exel-20250728_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20250728_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exel-20250728.htm": {
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20250728",
   "dts": {
    "inline": {
     "local": [
      "exel-20250728.htm"
     ]
    },
    "schema": {
     "local": [
      "exel-20250728.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20250728_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20250728_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.exelixis.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20250728.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20250728.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000939767-25-000111-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-25-000111-xbrl.zip
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M'M=#;S[XP&POYL(2%L7A \*91AT%B(R83Q]IO"(!N625?JS%ZK5XQWT&G3N
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M;M/\X:KM_U^LHS/L=WP]>@902P,$%     @ (H'\6M7=$&6JIP  A]@  !0
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M$1P#< 67-LD2UT?*I\=;.?\'/\)EENW/9AX>'J\Q!T*,&P&^Z<-?O[)/?8@
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M_Y44@'[P?K5U8:CX@%*0>\Y_)P)@9;J$,YQOK7#-"_\O)?SO+FI;[P!R"!2
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MNJK6K&?.9S[5-4:;/8_$EQE,O$ _H)#EZ)6VB<Y6#* #F#5S)T)$*G?:C6=
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MGK)\IN&0WU<+W=_&-FU-KAV^GD"81LID/1&D[.<^=A43Y1,E$\>PJZHBJ5$
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MZM"20OCO2$8KW;#-4\S8M<@,[BE=U(A/:(1)2<6<Y!/G]]=UZ)\QXF)#Y(*
M"UUZ(CEVUS%IHC+WG]VQ,$F4S\MB8G1FC$-;,SD%'4C?G^5?U?['":EW<%\
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M797N*&9P5]D9P],ZFU=\Y>VKW9-$F%9[Q23(-,.I>B:/<(D'CTC6;/9SYFP
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MY0DAS!;EK1VA&?_!2V,HMFLQEN-['F+21F@>B-COD08!<Q".LU;&8+(5U<+
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M7'TNL7NV=5:\EC<]*_EU^5 .*9G6^GEV@O^>XV04  8 A#)\U\>*C]@FPZ<
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MWPT$*Q]"NPM<)1[P1& S'^FN;G2X3>ZP!;WB0KK7-7@F.8SEA=0ML[L*8=(
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MKX**8=7P P!6<F(B\DMN2PL2"B+2P=AI5IID) .E$?,+:3O@I 8.#AQ0\Q^
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M*)&[VU4C#L?4(7"# ZTD^(4H4[^GQ41)2\>J"%@)-(1*TB(1=R<5@L:06A2
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M92C51(-SBR0TDPESMP@?S*L?N_+V3Y+]BUL]F_QC-I7'5*&XO;)./_3J5"S
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MM&1WR[T0-:%ARIS'>(4W*#TZE^];S#'X3H NSD^!9$!3'#[]'W9QUP(<]85
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M.S'FP7*^,II61\N:&#P"XRJ>[_L#L/S_7^OF&=54M^W]($VJJ(0.(B"]-R&
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M H>#@O&-N;1._=Z;X^4->9T3^:F8Z^KK.P.]/&LV0,U<2!KEDP4 '=[@2%J
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MR-WE[O(4AA8WV%FIV5F'\N&_,B"V)H8PQ1@\K56?73GX&I6GIV8,M4OL8"F
M/0"7)$BFQT["4UY&'P)25< ^U*&P)*D=AP6@7,WP/Y3FA"Y1KKN'J3AM\ZP^
MY00Q5VZ(;#TBJG378WQ3[MO0KFX[4\Q#PPCCJ^$8S #\&O"6?77@RT>1Y8F(
M#:;_ [HM3,Z7_0.;IX^#9SZG<*PH?>"OTP]W:IENY'G1,MWTC12'1N^9.?=
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MQ3_;"XS27O+J#N,W/X;TKI(U#'[*KJ=-%6LHR/40VFD9;.X/;2EJN1W#$MP
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M2T11*SY?'BUL*XU.5I/+V&HV&K4/M+C7C5NG==V'*ZTJ@VSW[13I7NJXJ@;
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M/3]ED:O$M&*&G>:AHRDLR2]Y?IG\FID@<UIZ7<R:D1T[/P&E.BGP$4GHQ0(
M /*_=;,12>/[K/R'[XA6V;#KC@Q(:01PL]W2\0- 71/<$D;![BQ%M^FRRS1^
M(-WY)V8O8F9A=6V"I86.-BB G%BQ?M$;'Z[BNG=]H@?=R6^ X1T+)\]]MQ[.
MQP1&]^%EY0]X<51ZJ1+P1*XG&]Z_K3+EV?IT=/R0.LVR=>%9_GE!HVE25'CR
M(QNO3VH]G>XZH\(GCGO<:'AE17D6R(^!P5-46_:X6FTSBJCQJ0T /U<),4JE
M .D=7:7V@&?-=/<Q*6&CEPER:OD1B7%@3H%RPI[4*\A@XZ0056V#(&W,,[(_
MD&5V\C6Q>.LP:(B)H+>9[6D&?Z1/4C^O+]5Z@2/.W>6@3S-7].I%DZ46ZH^R
M,$FOD^4^Y+S@L4>L@&^,T(IUZZ(0;'+.I-)SK)WZLT9^TLQ9]^Z<] 73;W$S
M,S.>-"]=#N#8C74JC14;2'4Q_2(YV:X5^YA;-OXWS8WX8MP4#9^2I2C>[ '&
M,SA$$>=BH1^__)[DVQNS*PZIVK>/Z';9 +5!_20?^UY3:M^C$/!BN098L%>-
M$=[RUZJ(DY.Q"AKS6K<*U$@P_UC1_B2UQ7UA2!#>REF0Q.P,OOL,9]]C6&%F
M6LC IUR<#")SP5*7Y!?^X8I"Y'7#*-\.[C,S 3VM(UGW64.GBYZ(NU$/7P2W
MNYHEXK?2<-&C1?:B$CP.2$]8M%:$VV#G(1IM^>RYOU*ZWBTG]21BE<\['\S^
M[CI=B[3B_101790[<UARF";>WG-*^7JXFC;VNZMA0$WV'D3;O@/.M+#!$17/
M;*?E8^0I;'!O4&RU#!-2K&)*\Q1%?C:2)80)T9-!]I@^^08ZFR>22U_L>_W5
M5<1MIT>7U[VOL4C"TCG_F9Y+_[(Z?BR"G80)(*+_[*\V;['<.RBD=5NK#@+V
MG9#XSAZ?3$*0!'T>A-9G(R!K\@EL%"J4T->:G(9"V34A$#X"M4D\.!S>!0#T
MIM0IUV]?ENC0VETBZ5V!?<KC%0C5EN&2&[!8 X#W?8'2CJHG=5280AK;4H#T
MT%1$_,79DD%M)=N*6"VLF (,9NU:M5-9Y!A6^^/V2K_/67-/M2$">7]I< C9
M$MNR/ZN1483!0BM;(/Y+?N&/+H*[.8X:^,ZEOC)')&F_-<-9W&7=B1X5'1OV
M[N8_!X5? TA>[YOXE<A>)BO%YQU&%/ZIQ9;+/JKMW184)?G*W&U(G=>@TO->
M7Y0YM.6(G;C#/<]1P:GI+<]'@=1)/0BT<O!]V V5PBE=8O;?:FRMR0$-64"3
M\^D9!L0H@,%K?Z"L54*@C&^U:UL#HP&%9\JP<I1!#>T+U]H,BH=P^_0E98G>
ML97+'0.W5'_WE 7J,T33Q59;VF=)>T&KL!''(:KA9K%E/04!9?@>75B.OK[2
M.+J])H+M:Y;@1*L2O-CQ@\*Z6@\,P;FVKWI?]=F>]ZA/%&CDS1%Z'S,HA4F?
MJ:FJB9-7/KREN)IV?*6H&>9ORW%$$IU%R%Y>FA$7'7QIMU%H/!7*O\@NI\PM
M9&BTX=6@?RO"5!;E\I3]"SE@AMBVV8B#AV)<:*T<>/"XJSR6I3RER>L+]\_>
MG+FT.?]VIG1<0ZU!R'L%[N[-)-]6JT,]B=OE[MRNC=CT@I9EKGC,ND&V;19[
M6]R>;6D\(G)J,=,QS;HLD<%_#""5Y318?6>@*IME#PQ*#&3\:V1P3R4G*SW'
M!(L=LBTI*'BEE0*6+;\C5:!0\68A.,\%9%0[MJH+CRFO7?MJ%1MNA"OS40]^
M*!4BH5:SH)$L>>Q\W(&H@>S($ X]Y!/PJHEB?R8IO&M@CAE6XIF["=*W?,&.
MD$Z>C%%;9#@4+7J+U^2=W/!9?<:#?[GB8&$/8C7:Z+?2&HB2@BU6NLD):%A/
MS [B61\@J7P3; H;EM%<+>:"HC==SK!2.7Y9470;=[AMR8\"[Q=1/M\:>WS\
M'6;/U?1Y2AH?#-U/787')D9-$]BEU*HPO)N>A$"55555[RBHJ]_@1RA36_&R
ML04#80  /N#QC4TBN_K% SV3.DH[K-FANZ:WV@<G/PSZ02362]4SS3IRP"!7
M<?L3?TG(]$>S]NW4SR:!9,BVVAPR<+[[>3JTV_%$T.)X^(7 H["1-6,P8<F[
M%O\1GHWZ2UHA7WM9FG^^59XB6XB;ZT;_<3/EXEMFUNS(Q:GI=!>\&G1!390@
M\"COO(S_2P^Y?\^L:P<S@T)J+3!-0')PN;+\3<:(OK&N_"V(OHR/WN"",Y?5
M3!XW_F31^WD2@;F/HJN'Y)D[%X;N)J"H38-N@7?%6U3)UNU\?D7=1 5+5OR9
M+_"J@Z3!^/_<Q*E%MRUE9@QYG/W;QH)))3/>#UB82E>/)O?-UL2M5?7Q+M=G
M-HI_TV6?_+TNN_ 4518"PIB4+C%D.:;*NJMLE!46WJ W8KH)BIRJ/']KUB45
M9*PWQI%I4DM35O>IIO>4L;P.2E'BI9EWREVHSEX4RK=J:["J$2E818? -<&+
M%>7^IR?M_%DL[!"A/&W%U4$G]0D\B([H:,T.8Y&I!3&!!WYS[6^#A=JCRX$:
M8Y2,80V?XN8^-;4S?7]S7($9>V39.3.E^2RK>*=:8X2"0O96)WU<DW_S<B[\
M_WM$P?FB_[V5]ON$I/U5H1-%F)+IZ+Q&O^4UP$04VEO2.!K(CDKG3W*Q*ZVR
M2_^1X4RG[=8\&ASF%U7-D'H'2,W+_0EF@_C@-L7",FF*N\=O8+;3&GW9K0;D
MS7_%MM+'Z'\G@B7N/S/H7[U+O,SL )]]M-BKK H<5V62"NAM#SDWW?MI5N9V
MBOVD[;',XP*:D#+I%5OE%X4O?_)RTP)+5!86[ASNOXXSB]W.<8^K'(,@GT-,
MDT.<6K.F1[4EF-R&VF_'57?/O*^R^&W0.X[&JP855+!]^I&QO(S.[>F6V3U'
M]8 M&IL(T(C:IEIM8./#D*GQ$N W6*W_J>)W\MM@#+F$(X4 O\BO"J92 YWN
MS;\CKH#%8)H! #J -/5KV48=AF7DL &<2"DRN66>SIJ#.;'P^6U<AM^Z8O*J
M*RJY8\LMD^<CMS7CE+9X!($R,\=/[59Q,KV:6?C(6U1+] =LEY6(B4.".,(V
M^'2 1L;+6SG]4.<,=PCR\C2.CR% *^^HBQ#::WD=-4MYW"Z\!K"W+@F=M Y@
M'%DT>,Y]FY+2GPQ,!3Z*:_!5"%("%[I8Z%J^F_ZX;)A*>R*>="1.<R%:= HJ
M.Y75W__$E!1BC8Y[J,)?TF(]7E(OQS#(#A@2OZ-*QX77-BP_GT\TA&S=>:Q5
M(LWUX\_8H!!F\.'%EV\2.O3'$%FHO$-50NFU:T"IHW:VX&Q"KM@/4&Z()=]]
M([3 00^1.'5&L\H.SCSS\P+LC@SQ<>SW5)=,S!\WV#0NO9(VN8R%1S!J$RYT
MS%QE[_O=L1^&P]<<#A]2"<XP]FX"C9= ?UCJJ$P9-IB47^S'LYI6U<V7BPE_
M_";G$+RU1.[Y_/P6:9U]!?4&7!(3M76E!RTO#11V>S=@JFRHS'8^.3,]0G9+
M2PWCV8VQU9-$6]WZ +)F*H#6$1QUOH^/ J;P67P257.+<W!I\*++U9'*"'H9
M62\KT+RX$4!2T3E$42D,TAC]X7@%><-:MHFDVBP(%JV?XZ\A\:4/U)/P,@DN
MR08&7_K1'=- BAI7'L2JFF8\[<?LZ@*Z3AL\:!)#<0ID2]> WO-G8X\.&A#<
M)763N5]Q\#[KA*D![',;RC3]TU,*0TM+\32)65>$(SPM9G!WVL:3?P @D8+R
M_2H^Y>6;M4="X^Q9B&W24Y.LWLFR7O>;/?+^%/39M1*3Q9OQPZZT\C$[?KZO
MZ"Q&U?5B*?X&N%C#@4(@>E5+H9<.;:/M+W($<P#0X57?NM*_"E]];(P\MAW2
MOLO3QU7ENE-@;OKDA9?S-> A.%^S5W9"O1UY>/Q\.SN@L*4"'?O^,Y+X;_]D
M$O6[^--:GCTPA"@))XBLDS1M;Y^J\U5U@,/983PQ?OZ%N?(B_+ZK\1PIY<F^
M0Z#QV-DR#GK0"%O#SQH$5&;?OB"JW2/.5=6OO9$!"H%TI=:G(CC$ZR>Y8?%2
M73!E2"F "!!DHW74#5'@[_W;8!MD:,93+(0\6)X[:,XIRE<Y7XJ5<,[L9[U\
MA]6SSV8X?<Z-<_7A-/_X$:W0O?LR931F/]M0)_V@P:J8>@[GZ5\6WY2N5*E>
MY%)^M%#'DC-_QBG:7ILWD"&6K YNBR NR3/7%]V?(PN=K2H&2Z;C@,EQ9:Y(
MZ?2L5666BETY+AO,JYB[I0"=&.>PJ<9S"X-"$8L;&TZ\PEV\MN6J=#*EMR3K
MRG,/="JW+$%Z[]XIG@+3!-V,-N,T9>Z^ PQH=CB5&A, DTG]'] 09O%*C1_*
M:A0Z2\KT4I0O!6$]F+FO 7X6^0#%K;LN10$W2RRB&"&I)QN%NO,_HB8_[RSJ
MTF!.RDPSS4VO0-3/_<,2'IKAHHAGT'M3"5&9F)3S%]GE0XTMR,['WR^HOP:A
M;C6==BY43,C E[ 'V][-<PQ%J&:0 +6"&U4_:Q0,U)O'&\%A)1%:4,#]1!YX
M6P6 ]\O378^/%Z\7_PM02P,$%     @ (H'\6J^3M,\<"@  ?54  !4   !E
M>&5L+3(P,C4P-S(X7VQA8BYX;6S%G&MOVS@6AK_W5VBS7W:!84V1E$06;0?=
M3#LH-M,&38H9[&)A\*9$J&T%LM(D_WXIV4ZE6)))*E91H/'E^+SG/=9C'LF6
M7O]ZOUP$WW6QSO+5FY/P)3P)]$KF*EM=O3GY>OD!T)-?W[YX\?IO /SUKR]G
MP6^YO%WJ51F<%IJ76@5W67D=E-<Z^#,OOF7?>7"^X&6:%TL WM8O.\UO'HKL
MZKH,$$31+FSW;/$*8LY(K$+ -,* R"@&5' ,%$IB%5-)&26_7+U22F*LN09"
M209(DD# DR@",$P0T:& ,F1UTD6V^O:J^D_PM0Z,O=6ZOOOFY+HL;U[-9G=W
M=R_O1;%XF1=7,P0AGNVB3[;A]WOQ=[B.#AECL_K9Q]!UUA5HTH:SO_XXNY#7
M>LE!MEJ7?"4K@77V:ET_>)9+7M9=/UA7T!M1W0.[,% ]!$($</CR?JU.WKX(
M@DT[BGRAO^@TJ/Y^_?*Q5Y+-JHC92E]5[^VY+K)<792\*,^XT M3?9VM?+C1
M;T[6V?)FH7>/71<Z[4Z[*(I6UJI*5E49QE65?^\3FXTH_YGJ+?=K?8;B:KN?
MGJO&H9Y^>K9R+\TGA#Y^P0V9T25O-JCW*S75MOLH-;KTXU?\7)M%7O+%!)O%
M#YE&R8OJ@3-S:RM3)1KX,*UUMA_=C5+U?:E72F\^+5NI@TR].3&WYDIG\XM\
MD<FL-,OB'Z:B(N.+N= J49I*0+!29N%2&%"()(A0&*6*048AFY>/6_1<K\#7
MBYUXK3"4_L3!5=E#9Z'7^6TA-^N:D:S6]$T5;W\(!CO%U[,?E3DW8W%DBXNC
MN<ME*^NB6I;SXJF)7!XP\6,C7QL7M8.UEB^O\N\S\\)9-?M4-T!UH]ZV>]+-
M]EK_KMA5R MYH%?;B)G,S;1Q4X)6V](B7]I8*7.;=VW3+B-X$N2%TH69'CN*
M;VTW?Q99:6@[S9?+VU6V&7_6\P2+*(%$ *Q1"$B<T&H A( 1B2$AD8J0MN6H
M4^'(*&TU@[:H/4W=73D,U&BO;DPYVG3":M"*%UG=&2>#:]!0DZ_A0'?$JKV*
MQ?EUOM*?;I="%W-*$ F51"#1D !"4@H8U1 H@6*A$"8"*5NZGB8_,EBU7%#K
M!1M!>ZCV^G"8IS'NW%!R,.:$49\#+X+VDDT&3Y^-)C>],>[(G.;?=?%.K,N"
MRW(>&4XH8C&(..=FM$,:<(P14#&-H P3@:/8EI=6YB/#4FL%_]VI_<\>E;;_
MPYQXNW*#Q-J0$R*=Q7OQT<XT&1R=!IID= >X8[$[TO>X<_N;&0#G"B<F$D.0
MB-@,:QJF@+,4@0@+Q6C((Y%8#VN="D?&Y/'XY48T,*I!)6N/2W=?#F,SVJT;
M/LY&G3 :-..%4W?&R; :--3$:SC0';/S0E?#GS855FDOJX,1Q><T-2.+I#BA
M4<)!&'(-2$(AX!%' ,504<T3C"2V9:U?YLC &6$@&\K!1CJHM>VI&VC38?2>
MQ[P;?WZ^G2 \;,N+Q(&TD^%XV%J328MH=S#?K\JL?#@U^0J^^&@RWO];/\PI
M@EB8?R 69D8DBC# -,< ,R4X23 .B363G0I'QG&C&6Q%@UHU,++V)';WY3"$
MH]VZ\>=LU F]03->U'5GG RX04--UH8#W3%[9XA5%;4?%OQJSD,*([.G!;!.
MH%GR. ,":0ZDEE0QR9(PI+9XM3(?&:M'K: 2LX>I[?XP1-Z>W."QM..$3&?I
M7JBT,TV&2*>!)AK= :-'PH_K]:TNFA-/*E*DJ=D)8YQ+0XD.@;EG*$&1D#S4
M28I]!\,]L:G'PTT!SS,E[G?.>58<U8^1$Z-+*\8,CKT>GV-\W$_^LX;(7IL#
MHV3_:WP'RDM^_U&9S%FZ/=J_/3Y-$D$B!@F@D"6 A# &0D %"(LD22*&<92Z
M#98]2M,,F$8\:*L['\(?[I?MP/D,7? :/-T;X#& 'C W8A#MRSSQ0'K X/Y@
M>N@%OMB^7^KB*EM=_5[D=^6U^8BXX:N'.802249C( 6/ ,$Q QQA 1(4HEB0
M! D1ND';J3,-LCOI8*,=;,5=@>WNE"VNH_U[P>IJW0/506,C0.W..S&F@^;V
M(1T.]T7T0[;8?=E+8HRAC!20) S-@ PCLYB:43G6,0X3&2.DK;_T?II\&A@K
M/<\5L]$'6^K\W'FA9F/, Z]]!R.8:B2;&*1]&_OT=,3X(O-%7V75%X6K\A-?
MZCFBD2!<0Q"Q" .BE-FOY#0%*4R8"C6F!$DW;-H"TZ#S0S.H1%WQ>=(36X3\
MG7IA9&O2 Z5N)R-P>I)P8J2Z[>QCU1/GCM:%EK=%M<K=RVOSSNEZ,^*((<ZY
M!E1A,RDR+H"HOM#32NF$LH2DS!JM+H$CH[63#'::CFAU]N0P6F.=NJ'E:-+M
MA\,#3OQ^.MR5<+H?#P_8:?U\>"C.':W+@E=GIET\+$6^F.,HHJ@Z^$E@* !!
M"@.&A0()@82&D@O(D2U3K<Q'AFFK%6S$["%JNS],C[<G-VPL[3CATEFZ%R?M
M3),!TFF@249W@.\@]W$E\^(F+^I#'A<E+_5I?KLJBX?37)FY+@EY'*KZ"S4-
MB(@I8"@U*Q!B24Q$E&IB#8J%WC1C7JN$7X*Z"-.U8%M(4%7B.OL-M]%V%'RV
MYGA-AJ/ZXC$N6KD=,3T.YY]XF+0RNS];VKW,?]0,D;C,RH6>AU1&,M8I@$0E
M@%0_'J,80X"I(BRA"$MF_2W"T^3'7A4KC2!/@Q#]0_PSV*F[SYB/S;"?+WTL
M.BZ2CNZ\ALNG-D8-EH_))A\JG]KH&BCW8GQ7SG=*F;=M74/YN3@O\N^9*71.
M*(Y)C$*0IL3LKRG! ",H D+'@D-).&6.1_:[A:99*[?:C=5@I^^Z0O:TRW9I
M'-\$KS71P[_'2CAL;L02V)-XXK5OV-[^HG<@?B2PY_FZY(O_9#?U: 93PB,D
M(%!AM2N(I9EP!80@T8(JLR.H(OM?Q/3+3 SK1CLPXE[#;&>C'$'UMC\.4UOG
M_I!V&AN/:#OMSP&TTUHOGMW1(^$\-3<_%Y?YW6K.&1(*)0*D$H<5F2F@U>D,
M5!@R8T$%UXZ_:]G3F!C+2KA:0BII3R8;_7$$TL_U.!JM#/NCN&]I/(>-G#\'
MPGU3O01VA([$;_OG+%OI<"ZPV>W3E #%DNJ,/1T"829;($,J8,)IFD;6ERGI
M59D8P>V-H-(./J]\E\96GQQ!]'4_#D5KX_XX=AD;#V0KZ\]!LLM8+Y2=P?XG
MT5Z:E\XIB12#B00,4S.DABD'5+$0\% QA"ADTOZ"0<W$1X;O\4S22LO]/-G:
M^F&X? VY\63GQ>M4V&;AH\Z K1--?N)KL_RN\UU;SWM<9*%"J]"\W@F1:9((
MK5- 8$( B30#(C$TL BG,8XH9<+ZR_!FXB.#4,]!E9;C[EC+^V$2?!VYD6!I
MQNWB"AV5^UU;H9EHNDLK=)3?NK)"U_-]*#0[:E:1;V]?[![)-E?K?/OB_U!+
M P04    "  B@?Q:W)T O*L&  #J,   %0   &5X96PM,C R-3 W,CA?<')E
M+GAM;,V:6V_CMA+'W_,I?-S7,S&O(AEL4N2DNP?!2;O!;HH6?3%X&=I"92F0
ME(WS[0^EQ-UDDVV%R$#TXHM,:8;_^4F<&?/=C]M-,?N"=9-7Y?&<'I+Y#$M?
MA;Q<'<]_O?H >O[CR<'!NW\!_/Z?3Q>SGRI_L\&RG9W5:%L,L]N\7<_:-<Y^
MJ^H_\R]V=EG8-E;U!N"D/^VLNKZK\]6ZG3'"Y&[8[M?ZB'!K1!8H&&0<A)<9
M:&<Y!*:RD&FOC1;_7AV%X#E'B^""-R"4(F"5E$"H8@*I(YZ:_J)%7OYYU+TX
MV^ L3:]L^J_'\W7;7A\M%K>WMX=;5Q>'5;U:,$+X8C=Z_C!\^VS\+>]'4V/,
MHO_UKZ%-_M+ =%FZ^/WGB\]^C1L+>=FTMO2=@28_:OJ#%Y6W;:_Z/_HU^^Z(
M[AOLAD%W""@#3@^W39B?',QF]W+458&?,,ZZ]U\_G3\QB5LL\FW>'/IJL^@&
M+,ZJ!,2E777N]J>W=]=X/&_RS77QU[%UC?%XWIT,75R)8KHS^L/7DQ=?[5_7
MV"1H^OE>I ,/U^BLO<X7W+98!KR?X\Y*4?DG@XI.X:K>G5E8AT5_=!DP7_97
M/G5-6UO?+DUFHW-, 3*C$H4)0*<R!,4(LJ 4\]$]G7KG=I/\[@/2H#]<55\6
MZ<*+3H[N0Z]+K\DS<_?:O,[OTW3[A>X6_%#8U9(X8J5"!RB)!Z&- *>9AN"T
MU4PX1R(;Y?<3<T_]?AS5T]K/JCI@G1XB.WNV]L\B_!3?AQ&+:UNG"X%?YT78
MG1WK:K./:+75/K2[CTSR=SY+TXY8UQ@N[@/SW=GU4VO3LQ7[D6."OGOL7F*=
M5^%]&7Y*#]^EE!%)2).GF10@!/?@T!F(F:'":<TP"Z."_Z+901"PZ4(P7LLW
MAN%]V>;MW2=<Y9T29?N+W>!24QF]E@&,[_Q7TH"17H!U1GG-.1.1CF+A):N#
M4.#316&TDI,@X2QI5=OB/"V(V__AW=)HQE+2I( B$A D6K 4)23 ,V6L]2[+
M]H#"-V8'L2"FSL(8+2<!P_L-UJN4O?^WKF[;]5FUN;;EW1*S2(E7 FCLF-8!
MTS1B $DRPE*Z[56T>T#B1>.#P)!3!V.\KF^,QV?T-W6:"&7N*F\+7"HJHJ1>
M S4\Z9&R:3"&$N""9E2'R W!44Q\:W$0"-ET01BEX!M'_ZJV74W_^6[CJF*9
MZ4PRQP2PF#%(N4["5DL"3+GHO6!.D7'5SA-S@^*NIAOWUVLWD5O^_=:O;;G"
M/KV)1#*?40G!8M=OL0J<=.E3)I +R[3V?B^W_6.K@Q#0TT5@M)*3R T^Y 7^
M<K-Q6"\CY5$1E:6%*Z$L7$IINE0'HJ!<$N%3#2SWD!!\M3B( #-= D8I.(GH
MGY>^JJ^KNA?]<](>SZJ;E.W>G54AU;_<6AZ%!I7%E.AFG(%S+@#WA%J%PJ<J
M> ] _*T3P]I+9.J0[$_H27!S9;?G(<F7Q_R^8_UP V0V93W6&TB+7IH(IQ8T
M,1Y"E))%QB4GXUJ/?VM^&"L3[D7N3]Q)4'(:0HI!\_!VD9=(EZB1D:@%A%0.
M==51!H[*"-JB-U(Y:JS> R$OF!Y&QX2;E/L1=4IDG*6/'^NKZK9<>A6B5ZED
MLL';KF[*P#),,[*48R V"KN/!M4SP\.HF'R_<IR@4V*B7QP_UI=U]24O/2Z-
MUYZJ1+2G.G9L$S#,"% R."-E0.7(_L#XQOHP.B;?P=R#M%-"Y+)J6EO\D5_W
MR1,E3(=H BBE) C!,C FN"2-9R[I)O7(GM7W;0_#8_)]S-&ROC$<W5/OM$;;
M^YTF[SD1#C+2^:TP@J7>@Y$&.3&$"<='X?#8VC  )MR_?+5T;QSR;J=,<;FN
MREWIC90I:K6$&*D'@2D/LB8Z2+DQS3@)5JEQ+:QO+0X+_81;F*,D?./P_U;G
M;8OE6;79W)0/55*S-)S'&),2MJN-!.&)7T\B,)Y):BTR)\TH!EXT.PR$"3<R
MQXOYUCWMJLA]WN;EZN>4X-2Y+9;,9=PRIB$5S4D+3A++6BO0FG&D7D?IQ_VY
M^=SF, XFW,X<*>,;0W!98T<PIL2VV\ESU>T%K#_&Y,?29UQ8'0-$GV00G!E(
M^F@0C+N4QTA*Q+BUX?NVAVV,FG#[<D^R3@N.\Z:YP?KQ7&+&B.;)>4D-3ZD/
M%6 M"R"HSH03A 8U;NGX)P^&@3+AWN5>)9[(ULJK-':IG><"5;?MRR7,HTZ%
MD.:^>R1&3]+J:$9NG7IL;1@&$VY2OEJZO87\W>*9=A?IP,G!PP_=2[<U_N3@
M_U!+ P04    "  B@?Q:'/[Y;_$W  #-1P( &@   &5X96PR,#(U,#8S,&5X
M:&EB:70Y.3$N:'1M[7UI=^.VLN#W^168SO+L,Y0B:I>=V^>XW>[$>=UN7]N9
M9.;+/1 )28PI4N%BM_+K7U4!X")1MN1-E,V<>]NV1 *%JD*AJE#+SY-HZK[_
M>2*X_?Y__?R_:S7VT;?BJ? B9@6"1\)F<>AX8_:'+<)K5JNIIX[]V3QPQI.(
M-1O-#OO##ZZ=&RZ_CYS(%>_U.#__)/_^^2>:Y.>A;\_?_VP[-\RQ__7.L7G7
M%$VSP0=VI\U'8BB$&'7-MA@U^(BW&_\QW\&K\+A\)XSFKOC7NZGCU28"YS_H
M-6?1X:UC1Y,#L]'XX5WNN4A\BVK<=<;> 4$+WXY\+P(H AA5_KHT^(J7]->6
M[_K!P7<-^N\0OZF-^-1QYP?_=0QO#0/GOXR0>V$M%($SD@^$SC_BP#0!4OKS
M5H$.[[N.)_12S";"?_)MX@R=B T&=3,/XS(:># &3$3^[& P0SB=Z9AQ-P*\
M3OE8\/I?L_$[%@;6P@?R;35KNS?[=JA&&OI1Y$\/.@#HC0@BQ^*NP@0A17ZM
ML=WKS+X5$:>D2*>1#IP('K?6(,,Q/,&M*/SQNT[_L(Q@MXO!G@1.R"Z%YXE@
MEZ!VQ(A]<CSN60YWV=?1R+%V:0$GWX3K?'-"@YUZ5GUWX.YV&K5^JU?K-=N-
M1T/='?+N"T!]2/#8PO(#'CF^=Q![M@CPJ7?OK9 X_\?ONNU#H6A2M_SIIFLK
MK; J)N-E#..Q7^/AD ?V3H!M-G'7_-]S@YW'0WB:'8U&W E"]N-WK?XA[*(;
M$49^P"Z$2T0.=V)5KT(6],U!>R=D ?#07;(@G,C]\"!A8('J*H)-I4'NK9=3
M&.72V)'G^;%G"3S_+=]+!,'S %/,1.QY)RW&P+]C'@#>R19Y,XM.M:4+$<9N
M%#+NV>P\\&\<L-7 0@MFN"D$^WUFPX_=8_H-%?8:N_(CPL:-\&+ @#]BWW>Z
M_7J+P;PN" >#'?.A_P_W(L=SANQ3 /B;."%@J'Y99V<B0NS9L14MC-%LU!MZ
MC-?$7ILB>*>8X9>CHW/VT7%C]&&<G%\2*1OU;L=@9[Y76_%U[U7)CU=-8##0
M1R(0<-[!MG9=DGY_B*'%PP@D@<WGC$>L0^9[H\'.O[ 3^$8$'KMRIH*M7FO>
MJ7*86?I?<1@YH_D+'^]'GX^^G'P\0N'E.J/Z5OCSQ^_Z3=,\W,HY]UOLSG_\
MSNPV#IM]8WM'?(WE]7JV=\9#F_]-#,9._CSYO,\B8KM P,&+8F64G-"!.J%'
M8-%$$\%"TL_8WTIO =F#ZS+83)[>-C SB^G89KZ'GXYAA!#&OP5]EG$XM<0-
M>F6OQ9Q9R4'O#_\25N2 Y630;O#C"!=B,P>F!KUW*@*$QF 6?(R^/7IJYLP$
M/L9L./1<?T;.7\ <VE^>".NLA#NEF$;(I<W&8:(/ X[AI(\! 9'/P "P8HE/
M/PX*L<8<[T[JV##N#8 &B(=1).Y3I&;1E\-KBDN#((1]%'+'9E\<:\*%R[[4
MV1<_")PP%',PAR?UCW7X 00'3E!C2?_8"2T!0-#^,2/AR3I3B_]C K,QP0-W
MKI?C<C *)@:[%;2->X>!8+",.9NY@H> G5LGFM"3@;#$#,TH^ N$Y_'1AZ]?
M3J[^WY^P_7KM0S;A(3T"$-@X.+=O@+_A=T_$@2\\V[<"7' 43WVPY/?.3J[V
MZ^PK85OCB46"3UG 9XX-$$[]H>,"A6WF2UBE)G9RI8"&#>.Z_BUBG,]P<\
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MS -DMA-:,8KW"7!7,C*Q72#&,; C;J=DEP+XR(,HR$9 6!?7AP=+=H=$8-?
M3QND/#T)M/X[=JQK8%7X%583.D-7U.$D@\TTI\7"'@6!@.>6\ +8=H06F,M?
M6%Y[>7D>*-26BWQF"1=/.P\7BK]:L%,=SY]R!;X_J^70)[[- "U2G. T(R<
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M>=>5=,&>>'EGYET ;L'#>Q<X]\B+TO+ N_?R+C+0]XC;<%EK9[,VPL"(!A,
MG1MR@[8:<H."(0):B+PJE=\D]Z6<_,8S'DC;\?MNJU=OYIY)7-KR.3KN9P"O
M3R8]#-_>(0?R M'61J#C66YLDR.4/$ETAQRLO$->QFL;\-K=&*]7Y S"..U0
MD!NF:/9;]/<$#J :\ 2VN9 V>.[%D+OPY U83%.Q.F"I;-0Z1O5QJ*1&LF"#
M,.:32V@$QB=H_>144^A B]3*O0BSWS@8-)..(#=$N[^*U^]CB&4"FZ":/HS
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MDB;/EH$W6,A7J)RJ) =!6G:25*34UBF_%AF55:<"E-(GM<+@OA=+J-0[:?H
MV4*HM'*PEX8 <H29?J""DHL&3"@D4T!/)4-0[HP>.*NYWF>?9$@L0$./T1T9
MIG8*DL""][4%(NTC=;DMS0ZBJK)U..8!8/9R2(]DS#VW" -90RJUT6$6M 'E
MQT,1W0KA*5[+6J!@M"%_H"8BH4O9ZPY[YB(W?)B,3Y!1PHL&4Z\/J9-S@E!R
M"6[L4!K!#EWTX_U1&9ER4Q_7PGGWBTJP*Z/[[AX'!OQORD$"P?]U& C0\<;Q
MXQ"X)4E.7DXF)'-OY(1X14[YAHB31SHP=\:DZ?;JS<9ZJM]&&F6CWAFLK:@6
MG+(:-; _Q9JZIT(S*AH'P#L,3&O'9LAYA^HK)-G"-QMJ+##"\ZHKQ898/K;O
M2:\X>G6SLP8,!6X.Q&:M5>\7L"BZBA9B<N_5J^XG7R"A>0+2ELC&_KY9!PD\
M5/?<-09_MY*_<Q9WM5'NQ^99011I*3GP =;@,]=G6\F>C07V-)?8<Q<$T9ZY
MOS8CE'I/O23UC_V0?.MC'PU%@-Q>0R*]44'>_@&V1^<'6;[C#BE4L=V]J+PW
MS)B5C UW1IH/0->8IL)\T.L\2VW YY;ES4J6;TS[38*:J_WUP/W5[N7V5Z>Y
MF_NK]1+[2WDXBOGCE6V^$XJ!H!I,_!O5_EE_AST43Z]2RVJ:J&8U6S\\1I_*
M7]1DY(?"@<)J7V/!\3":YJ"&GSS5>@=K>3?_4_#?2L=D#OK!(O"#IX.](^7'
M?>"O%C_F?:;:TX;QKH?KQ5L$<HT7IJ4FGN, 0XYT!FTH"YQ1^#=: 5S&2]Y.
M?%=@WB#CUM^Q(S%"65AI#@TF*-;[/Y G.JVX)Q*A\1OWZLR4%Y6K;QU>#?V;
M6Z'_J2;C][FT4[3G=*3:JD"X-T"3UI9ITG\ZFNS.[5Q1<,JO\*:+;X=EO*1;
MT8^JN'1]8=5Z-$LN_#EWL3S@=BI&%WF1E=FD$GLH^2&[J%&R*"=3#%85I\C6
M3[@W3;UCR.OZU>48S%Z:S2EC8],S8R\+U;[,XFC6S87'\>&+TW^KTKCY=W1-
MRGB&QU3FFYJ.GBT^$[/H63Q*\[G_&,(-#X=%Q1;3U!F6YCJE,0L\P)+0W[=;
M]78V2S\@?IDGT#QA^LF06]?CP(=-65-\-Z+_#I\]OU-B254HN-"EBX]TH=2D
M(.A)'/@SP3UV[$]UD<.]D^/]!6T"_SK7Q0Z)P\[3Z_$KU2_Q*%,+LUXH\%\
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M%TK0[%X@UE?Q%2NVP,ZX[H[R>SP]P^2V+7+8P>*30)_,]?IVLI87K].3DL?
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MG// #G-]?S-1*[88815'??3EZI3,Y,J%7#G8)T$8&4GR/7(R2:54)/T.AP8
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M;"TR,#(U,#<R."YX<V102P$"% ,4    "  B@?Q:U=T09:JG  "'V   %
M            @ '@$@  97AE;"TR,#(U,#<R.%]G,2YJ<&=02P$"% ,4
M"  B@?Q:KY.TSQP*  !]50  %0              @ &\N@  97AE;"TR,#(U
M,#<R.%]L86(N>&UL4$L! A0#%     @ (H'\6MR= +RK!@  ZC   !4
M         ( !"\4  &5X96PM,C R-3 W,CA?<')E+GAM;%!+ 0(4 Q0    (
M "*!_%H<_OEO\3<  ,U' @ :              "  >G+  !E>&5L,C R-3 V
F,S!E>&AI8FET.3DQ+FAT;5!+!08     !@ & (X!   2! $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>exel-20250728_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="exel-20250728.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0000939767</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-07-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30235</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Alameda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">837-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock $0.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
